NCBiotech News

Precision BioSciences, a genome-editing company based in Durham, has received authorization from the U.S. Food and Drug Administration to advance its second genome-edited cancer therapy to clinical trials.  

Durham-based Arbiom is challenging the world of animal feed by utilizing wood waste as a source of protein.

Durham’s Mycovia Pharmaceuticals is one of nine startups scrambling for last-minute votes in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco this October.

RFPi, a Greenville medical device company, has landed a groundbreaking $1.49 million NIH grant with ECU as its academic research partner.

North Carolina is taking an increasing leadership role in precision health as we apply new technologies to our deepening understanding of how people’s genetic makeup and other factors impact their wellbeing.

The 11th annual Ag Innovation Showcase will connect the relationship of health in food production and the environment. The Guthrie in Minneapolis will be hosting the Showcase September 9-11, offering expert panels with rapid-fire discussions, spotlight sessions, and representation from multiple agribusiness companies.

Registration is open for the Sept. 25 and 26 "Invest in Cures & Rare Disease Forum," bringing together potential investors, collaborators and NC therapeutics developers to find new ways to deal with orphan diseases.

Viralgen, a Spanish contract development and manufacturing organization half owned by AskBio of Research Triangle Park, has gained vital regulatory status in Europe for producing gene therapies using AskBio’s manufacturing process.

Thermo Fisher Scientific has a new virtual reality training facility that will mimic real-world operating environments as a way to train new employees on the sterile injectibles drug production lines.

Durham-based Aerie Pharmaceuticals, a developer of therapies for eye diseases, has begun patient dosing in a first-in-human clinical trial of an implantable drug for treating two retinal diseases.

North Carolina’s Raleigh-Durham metro area, a.k.a. the Research Triangle, has the nation’s fourth-leading life science base among major metro hubs, according to a new report.

Pyxus International, a Morrisville-based global agricultural company, has signed an agreement with Cornell University to fill a gap in hemp cultivation knowledge.

Research Triangle Park-based GeneCentric Therapeutics has acquired a sister precision medicine cancer start-up, Chapel Hill’s Select ImmunoGenomics.

A window of opportunity is opening for qualified Pitt County high school students to take an industry-focused training program after graduation and enter a rewarding, well-paying career in pharmaceutical manufacturing.

North Carolina is a global leader in gene therapy thanks to its renowned workforce development programs and the scientific output of its research universities.